HEALTHFORTUNE
The FDA’s peptide vote could create telehealth’s next multibillion-dollar market
The FDA is considering approval for compounding pharmacies to legally mix wellness peptides like BPC-157 and TB-500, which could create a $30 billion market. Telehealth companies like Hims & Hers, which previously profited from compounded Ozempic alternatives, are positioning to expand into peptide therapies despite limited long-term safety data.
Mentioned
Related Signal
Adjacent reporting
- RFK Jr.'s peptide push could become next wellness boom
- ‘Wild West’ peptide craze surges beyond GLP-1s as FDA faces pressure to ease access
- What's behind the push to make peptide therapies more readily available
- The peptide beauty boom could be worth $2.2billion more... but one FDA decision could spell doom
- FDA to weigh lifting restrictions on some MAHA-favored peptides
- What's behind the push to make peptide therapies more readily available